Pazopanib After Sunitinib in Metastatic Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Phase II Study of Pazopanib as Second-Line Treatment After Sunitinib in Patients With Metastatic Renal Cell Carcinoma: A Southern China Urology Cancer Consortium Trial
Eur. J. Cancer 2015 Mar 01;51(5)595-603, M Xie, CS He, JK Huang, QZ LinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.